原发性肝癌肝动脉化疗栓塞术前后血清IL-12和sTNFR-Ⅰ水平的改变

目的　研究原发性肝癌患者肝动脉化疗栓塞术前后血清IL -12和sTNFR -Ⅰ水平的变化及其临床意义。方法　采用双抗体夹心酶联免疫法 (ELISA) ,检测 60例中晚期肝癌患者肝动脉化疗栓塞术前后血清IL -12和sTNFR -Ⅰ水平的改变 ,并与健康对照组比较。结果　肝癌组治疗前IL -12水平降低 ,sTNFR -Ⅰ水平升高 ,与对照组比较有非常显著性差异 (P <0 .0 1) ;肝动脉化疗栓塞术后 ,患者血清IL -12水平升高 ,sTNFR -Ⅰ水平降低 ,治疗前后比较有非常显著性差异 (P <0 .0 1) ;应用免疫调节剂组较未应用组血清IL -12水平升高和sTNFR -Ⅰ水平下降更显著。结论　检测原发性肝癌患者血清IL -12和sTNFR -Ⅰ的水平 ,有助于了解患者的免疫状况 ,肝动脉化疗栓塞术能改善患者机体免疫功能 ,给予合理的过继免疫治疗能增强这种作用     

Preventive and Antiproliferative Effects of Tumor Necrosis Factor against Experimental Hepatic Metastases of Mouse Colon-26 Tumor

This investigation was undertaken in order to assess both the preventive and antiproliferative effects of tumor necrosis factor (TNF) in a hepatic metastasis model, by means of inoculation of mouse colon- 26 tumor cells into the portal vein via the superior mesenteric vein in male CDF1 mice, aged 5 weeks. Continuous 10-day administration of natural human TNF-α (nHuTNF-α) following the tumor cell inoculation caused no reduction but rather an increase in the number of hepatic metastases. However, pretreatment with this preparation daily for 10 days before the inoculation caused a remarkable decrease in the number of hepatic metastases. This prophylactic effect was reversed by the intravenous administration of anti-asialo GM1 antibody 24 h before the inoculation. The result of immunoperoxidase staining of liver specimens suggested that organ-associated natural killer cells might play a role in the metastatic inhibition. An apparent antiproliferative effect on metastatic liver tumors was also recognized following injection of nHuTNF-α from the 10th day after the inoculation. Thus, TNF appears to have important effects upon the host immune system, acting against liver metastases.     

Hepatic Metastatectomy for Low-Grade Leiomyosarcoma: A Case Report

A patient with multiple bilateral liver metastases from a gastrointestinal leiomyosarcoma underwent staged sequential metastatectomy and at 3 years is tumor-free.     

Dramatic and Delayed Response to Doxorubicin-Dacarbazine Chemotherapy of a Giant Desmoid Tumor: Case Report and Literature Review

Desmoid tumors are benign, slow-growing mesenchymal tumors. Aggressiveness is local with no potential for metastasis or dedifferentiation. The treatment is challenging, particularly in the case of huge intra-abdominal locations. We, herein, report on a 21-year-old patient with a giant intra-abdominal desmoid tumor occupying substantially the entire abdominal cavity. After failure of a first-line combination of celecoxib and tamoxifen, the patient was given doxorubicin-dacarbazine chemotherapy. The treatment was well tolerated, and rapidly, the clinical digestive symptoms improved. After 6 cycles, the computed tomography scan showed a partial response (regression of tumor volume by 55%). During follow-up, the tumor continued to regress: 25 months after the end of chemotherapy, the tumor volume had regressed by 95% when compared to the start of computed tomography and by 90% when compared to the end of chemotherapy. Thirty-three months after the diagnosis, the patient is alive without any symptom. Our case provides further evidence of the remarkable efficacy of a doxorubicin-dacarbazine regimen, especially in function- or life-threatening situations where a rapid response is required. We review the literature and discuss the challenging issue regarding treatment of desmoid tumors.Key words: Desmoid tumor, Chemotherapy, Doxorubicin, Dacarbazine     

Ureteroscopy-Assisted Biopsy for a Retroperitoneal Tumor: A Case Report

Introduction

Retroperitoneal tumor is often seen in urology clinical practice. To diagnose the tumor, tumor specimens must be obtained. However, in some cases, the tumor is penetrated by vessels around the ureter, and it may be difficult to detect the optimal spot for obtaining a specimen, even when performing open surgery.

Case Presentation

A 53-year-old male patient was referred to our hospital for further examination of left back pain due to hydronephrosis. Enhanced computed tomography demonstrated ureter stenosis in front of the ilium, which was surrounded by a retroperitoneal tumor. The tumor was penetrated by blood vessels; therefore, we performed an open surgical biopsy on the suspicion of a retroperitoneal tumor using ureteroscopic assistance. The diagnosis of idiopathic retroperitoneal fibrosis was made according to the biopsy.

Conclusion

We herein report the first case of a ureteroscopy-assisted biopsy for the pathological diagnosis of a retroperitoneal tumor.Key Words: Ureteroscopy, Retroperitoneal tumor, Retroperitoneal fibrosis     

肿瘤坏死因子基因多态性与非霍奇金淋巴瘤临床与预后的相关研究*

目的:探讨肿瘤坏死因子α（tumor necrosis factor alpha ,TNF-α）基因-308 位和淋巴毒素（Lymphotoxin-α ,LT α）基因+ 252 位基因多态性与非霍奇金淋巴瘤（NHL ）临床及预后的关系。方法:采用聚合酶链式反应（PCR ）、限制性内切酶消化及电泳技术,对中国广东省96例NHL 患者和72例正常对照者的TNF-α 和LT α 基因的单碱基突变多态性进行检测,收集其临床资料进行生存状况分析。结果:1）NHL 患者两位点联合单倍体分型在性别、年龄、分期等临床特征的分布无显著性差异;而联合单倍体分型的高危型在不同人群中有显著性差别（NHL 组70.4% ,对照组45.2% ,P=0.018）,NHL 治疗不敏感组中高危型比例明显大于治疗敏感组,相对危险度为2.887（95%置信区间为1.188~7.016）。 2）Kaplan-Meier 方法进行生存分析,发现高危型与低危型的无瘤生存时间、总生存时间有显著性差异:高危型组平均生存时间为16.19个月,低危型组平均生存时间为48.63个月,1 年无瘤生存率分别为66.67% 、87.50%（P=0.023 1）;2 年生存率分别为39.95% 、65.13% ,4 年生存率分别为8.32% 、46.52%（P=0.001 2）;COX回归模型显示联合单倍体分型是影响预后的危险因素之一（P=0.034）。 结论:TNF-α-308 位和LT α + 252 位联合单倍体分型与中国广东省NHL 患者的治疗反应、生存等预后因素有关,可考虑将测定两位点多态性作为评估NHL 预后的一种敏感指标。      

肿瘤坏死因子基因转导肿瘤浸润淋巴细胞的初步研究及应用

用单纯疤疹病毒(HSV)的缺陷株作为载体,感染肿瘤细胞治疗脑瘤的研究已取得了不少进展.本文报道将HSV—tk基因转移联合抗瘤药物GCV可使荷脑瘤大鼠长期存活.9L神经纤维肉瘤细胞用HSV载体hrR3转染,hrR3缺乏RNA还原酶,只能在肿瘤细胞中复制而不能在神经细胞中复制存活,同时还携带病毒胸苷激酶(tk)基因,RH105无tk基因,转染hrR3的9L细胞体外培养,加入GCV1μg/ml共孵育,结果发现9L细胞被杀死的数目比单纯感染hrR3的细胞死亡数目增加23%.GCV加到不表达tk基因的RH105载体转染的9L细胞体系中没有杀伤作用.将神经纤维肉瘤9L细胞4×10~4接种到Fischer 344CD大鼠脑前叶,5天后将hrR3载体2×10~7PFU/10μl直接定位注射至脑瘤部位.结果发现hrR3载体治疗可使20%的大鼠存活时间超过5个月,而生理盐水组全部死亡.接种病毒后同时用GCV7.5mg/kg治疗7天,可使48%的荷9T肿瘤细胞的大鼠存活时间超过5个月PH105感染的治疗组大鼠全部死亡,组织化学检查证明外源性的tk基因在肿瘤细     

细胞周期对肿瘤坏死因子诱导Hela 细胞凋亡的影响

 目的　研究细胞周期对肿瘤坏死因子 ( TNF)诱导 Hela细胞凋亡的影响。方法　通过胸腺嘧啶核苷酸 ( Td R)阻断法阻滞 Hela细胞的细胞周期 ,以 MTT法、流式细胞术和荧光染色分析 Td R阻滞细胞和周期化的 Hela细胞对 TNF诱导凋亡的敏感性。结果　Td R阻滞细胞周期较周期化的 Hela细胞对 TNF诱导的凋亡的敏感性降低。结论　揭示 TNF诱导 Hela细胞凋亡与细胞周期有关.     

Potentiation by Tumor Necrosis Factor of Mitoxantrone Cytotoxicity to Human Ovarian Cancer Cell Lines

The cytotoxic activity of human recombinant tumor necrosis factor (rHuTNF) (from 0.01 to 10000 U/ml) was assayed on six human ovarian cancer cell lines and one human cervical carcinoma cell line using a crystal violet assay. rHuTNF was cytotoxic to four cell lines (A2780, A2774, SW626, PAD, while 3 cell lines (IGROV1, SKOV3, Mel80) were marginally sensitive to its activity. However, under the same experimental conditions rHuTNF markedly enhanced the cytotoxicity of mitoxantrone, a chemotherapeutic drug targeted at DNA topoisomerase II, in six cell lines. The potentiation of mitoxantrone cytotoxicity was not caused by increased drug accumulation after rHuTNF treatment. No significant increase in cytotoxicity to Me180 cell line was seen when rHuTNF was added to mitoxantrone.     

Case Report: Inflammatory Myofibroblastic Tumor of the Duodenum

Introduction

We report a very rare case of inflammatory myofibroblastic tumor of the duodenum. A 16-year-old boy underwent esophagogastroduodenoscopy for intermittent epigastric pain, night sweats, and malaise.

Case Report

An exophytic mass lesion was found in the first part of the duodenum, but biopsies were non-diagnostic. Computed tomography confirmed a 60-mm mass with no lymphadenopathy, and the patient underwent surgical resection. Histology revealed spindle cells with the morphological and immunophenotypical profile of myofibroblasts on a background of mixed inflammatory infiltrate, typical of inflammatory myofibroblastic tumor. Six months after surgery, the patient developed a recurrence, and this was successfully treated by immunosupression. Currently, the patient is asymptomatic, and there is no radiological or pathological evidence of disease.     

Leukemic Cell Lysis by Activated Human Macrophages: Significance of Membrane-associated Tumor Necrosis Factor

In this study, we analyzed the mechanism(s) of leukemic cell lysis by human macrophages. Peripheral blood monocyte-derived macrophages were activated with recombinant interferon-γ and lipopoly-saccharide and their lytic activity against two leukemic cell lines (K562 and HL-60 cells) was assessed by an ¹¹¹In releasing assay. Activated macrophages lysed these leukemic cells, and the lytic activity against leukemic cells was almost completely inhibited by anti-tumor necrosis factor (TNF) antibody. The macrophage-lysate prepared from activated macrophages also exhibited significant lytic activity against leukemic cells; this lytic activity was inhibited by anti-TNF antibody. The leukemic cells that we used for the cytotoxicity assays were resistant to recombinant TNF. The culture supernatant of activated macrophages did not show any lytic activity. These findings suggest that cell-associated TNF plays a role in macrophage-mediated cytotoxicity against leukemic cells.     

Inflammatory Myofibroblastic Tumor of Mesentery: A Case Report

Introduction

Inflammatory myofibroblastic tumor occurring at intra-abdominal sites in children has rarely been described. In the abdomen, mesentery is a rare location for an inflammatory myofibroblastic tumor.

Case report

A case report of inflammatory myofibroblastic tumor of mesentery presenting as painless abdominal swelling is presented. Histopathological study of specimen documented the diagnosis. Complete resection of tumor was done with no recurrence seen in follow-up.     

重组改构人肿瘤坏死因子治疗恶性心包积液28例

[目的] 探讨不同剂量重组改构人肿瘤坏死因子（rmhTNF）在恶性心包积液治疗中的疗效及毒性反应。[方法] 28例肿瘤患者分为两组，分别于心包腔内灌注rmhTNF1500万IU（大剂量组）、rmhTNF500万 IU（常规剂量组），连续治疗4次。1个月后按WHO标准评价疗效和毒副反应。[结果]rmhTNH治疗恶性心包积液疗效好，大剂量组疗效达到92．9％。常规剂量组为57．1％。而毒副作用两组相似。[结论] 大剂量rmhTNF治疗恶性心包积液疗效高，而毒副反应小。     

介入化疗治疗多发转移性恶性纤维组织细胞瘤1例

1资料 患者,男性,59岁,2年前行右前臂肿物切除术,病理:恶性纤维组织细胞瘤,术后未做任何治疗.因"右胸壁肿物2个月,右胸痛、胸闷、气短一周"入院.查体:痛苦面容,全身浅表淋巴结无肿大,右胸壁可触及软组织肿物,约5cm×6cm大小,质硬,固定,压痛.     

Malignant Rhabdoid Tumor of the Breast: A Case Report

A 66-year-old woman time of 10 days. One month after radicalmastectomy, there was local recurrence, followed by multiplepulmonary metastases, and the patient died of respiratory failure5 months after surgery. The gray-white-colored tumor measured13x12x;10 cm, and its border was well defined. The tumor wascomposed of diffusely growing round or polygonal cells withvesicular nuclei, prominent nucleoli, and ample cytoplasm containingeosinophilic inclusions. Lymph node involvement was widespread.Both vimentin and keratin were clearly demonstrated by immunohistochemicalstaining. Ultrastructural studies revealed that the MRT cellscontained cytoplasmic whorls of intermediate filaments.     

大网膜颗粒细胞瘤1例报告

患者,女,55岁,10年前卵巢囊肿手术切除,5年前因子宫肌瘤做子宫全切除术。3个月前自觉右下腹隐痛不适,感觉有牵拉痛来院就诊,查体:体温36.7℃,血压正常,腹平软,右下腹触及鸭蛋大小包块,质不硬,界清,活动度差,有压痛无反跳痛,实验室三大常规检查正常。临床疑慢性包囊性阑尾炎,收入外科治疗(手术)。术前CT检查表现:平扫见右中下腹脐旁见一大小为12cm×13cm×12cm类圆形软组织密度肿块影,边缘厚薄不均,伴有结节状软组织突向肿块内,肿物左边缘呈环形网状,病灶中心密度均匀,CT值为27.3Hu～49.0Hu,同时见脐中线左下前腹壁内侧一类圆形大小为2.0c…     

Ossifying Fibromyxoid Tumor of Soft Parts: A Case Report

A case of ossifying fibromyxoid tumor of soft tissue parts inthe presacral region, which developed in a 46-year-old Japaneseman is reported. The enucleated tumor was an encapsulated, elastic,hard mass measuring 2.5x2.2x1.4 cm. Microscopically, the tumorwas characterized by foci of round to polygonal cells dispersedin a fibromyxoid matrix, containing varying amounts of collagenand osteoid tissue. At the marginal zone, the shell of boneand osteoid tissue with calcification separated the tumor fromthe surrounding tissues. Our patient is showing no evidenceof recurrence after a one-year follow-up period. The findingsare compatible with those proposed for ossifying fibromyxoidtumor of soft parts by Enzinger et al. in 1989. This tumor shouldbe differentiated from cartilaginous, osteogenic and neuraltumors.